Introduction

!
We previously reported that early postoperative medication with a proton pump inhibitor (PPI) is the most effective treatment to prevent gastrointestinal diseases after open heart surgery [1] . However, the patients undergoing heart surgery usually take concomitant warfarin. The American Food and Drug Administration (FDA) has suggested that lansoprazole increases the international normalized ratio (INR) when used concomitantly with warfarin, by being metabolized by cytochrome P-450 (CYP)2C19 [2] . In the clinical situation of post-cardiotomy patients, however, side effects of PPIs used concomitantly with warfarin have not yet been reported. The aim of this study was to review the patients taking warfarin after open heart surgery, and evaluate whether PPIs have side effects that emphasize the anticoagulative effects of warfarin.
Patients and Methods
!
A retrospective, observational analysis was performed in 240 patients who took wafarin after cardiac surgery between January 2005 and August 2006 in our institution. Institutional review board approval was given prior to publication of this manuscript and reporting of the information. One hundred and sixty-eight patients (70%) were male, and the average age was 65.7 ± 12.0 years, ranging from 20 to 86. Individual on-pump coronary artery bypass grafting (CABG) was carried out in 112 patients (46.7 %), individual valve replacement in 61 patients (25.4 %), concomitant CABG and valve replacement in 21 (8.8 %), concomitant valve replacement and Maze procedure in 15 (6.3 %), concomitant CABG and carotid endarterectomy in 6 (2.5 %), aortic root replacement in 8 (3.3 %), and other miscellaneous procedures in 6 patients. Surgery was performed by two surgeons (K. M: professor, or M. H: assistant professor). Five resident doctors randomly gave patients lansoprazole or rabeprazole as a PPI. Although some patients took other anticoagulants such as ticlopidine or aspirin, no patients took medication which strongly affected the antiAbstract ! Objectives: The American Food and Drug Administration has suggested that proton pump inhibitors increase the international normalized ratio (INR) when used concomitantly with warfarin, by being metabolized by cytochrome P450 2C19. We therefore reviewed patients taking warfarin. Methods and Results: Two hundred and forty patients who took warfarin after surgery were divided into two groups: Group I (n = 114) had rabeprazole (10 mg/day) and Group II (n = 126) had lansoprazole (15 mg/day). The initial dose of warfarin was 3 mg and INR was initially assessed on postoperative day 4. Initial INR was significantly lower in Group I (1.66 ± 0.87) than in Group II (2.06 ± 1.03, p = 0.0011). Delayed cardiac tamponade and hemothorax occurred as complications in 6 and 1 patients, respectively, in Group II from 5 days to 3 months postoperatively. At the time of the occurrence of complications, the average INR increased to 3.95 (range from 3.11 to 5.86). There were no patients with delayed bleeding in Group I (p = 0.015). Conclusions: These results suggest that lansoprazole emphasizes the effects of warfarin. Rabeprazole could be safely used concomitantly with warfarin.
coagulative effect of warfarin, such as thyroid hormones, steroids, cimetidine or clofibrate, except for amiodalone in the patients undergoing a Maze procedure. Patients were divided into two groups; Group I (n = 114) who were given rabeprazole (10 mg/day) or Group II (n = 126) who were given lansoprazole (15 mg/day). Oral medication was started from postoperative day 1 in all patients. Patients undergoing CABG or aortic surgery took aspirin (100 mg/day), and those with valve replacement took ticlopidine (200 mg/day), concurrently with warfarin. The initial dose of warfarin was 3 mg and the INR was initially assessed on postoperative day 4. We compared the two groups in terms of patient comorbidity, level of INR and incidence of hemorrhagic complications. Statistical analysis was carried out using Stat View (SAS, Cary, NC, USA). The results are expressed as means ± standard deviation (SD). Statistically significant differences were determined using the Student's t-test and the chi-square test. Independent predictors for postoperative bleeding event were examined using univariate analysis with a Fisher's exact test and 19 parameters, including age (> 70), sex, operative characteristics, difference of surgeon, low ejection fraction, preoperative heart failure, preoperative renal failure, diabetes, hypertension, hypercholesterolemia, smoking history, atrial fibrillation, old cerebral infarction, longer cardiopulmonary bypass, postoperative bleeding (drainage volume > 1000 ml), requirement of platelet transfusion, concomitant usage of aspirin or ticlopidine, and type of PPI. A p value of less than 0.05 was considered statistically significant.
Results
!
The incidence of hypertension, hyperlipidemia, diabetes, atrial fibrillation, chronic renal failure, old cerebral infarction, and smoking history were similar for both groups, as were operative characteristics such as CABG, valve replacement and the use of aspirin or ticlopidine (l " Table 1 ). There were no differences in terms of age, sex, preoperative ejection fraction and serum creatinin level between the groups (l " Table 1 ). Cardiopulmonary bypass duration was also similar (l " Table 2 ). There were no differences between the groups in postoperative total drainage volumes or requirements for platelet transfusion (l " Table 2 ). Initial INR was significantly lower in Group I (1.66 ± 0.87) than in Group II (2.06 ± 1.03, p = 0.0011). The second INR was similar because the dose of warfarin should have been replaced by the doctor in charge. Complications of delayed cardiac tamponade and hemothorax were seen in 6 and 1 patients, respectively, in Group II from 5 days to 3 months postoperatively (l " Table 3 ). When the complications occurred, the average INR increased to 3.95 (range from 3.11 to 5.86). Pleural or pericardial drainage was required in all patients (l " Table 3 ). In contrast, no patients in Group I experienced delayed bleeding complications (p = 0.015). Fisher's exact test showed that only lansoprazole was associated with the bleeding events (p = 0.0151). Table 3 ).
Cases 2, 3, 4, 6, 7 (l " Table 3 )
These patients took lansoprazole and warfarin after surgery, and their pericardial drains were removed by postoperative day 3. Their initial INR was around 2.0 and warfarin was kept at the same dose. However, they began to become very sick and hypotensive due to delayed cardiac tamponade. Their INR rose to > 3.0 at the time of cardiac tanponade (l " Table 3 ).
Discussion
! Post-cardiac surgery bleeding from the upper GI system is quite lethal, because coagulopathy can develop as patients undergo anticoagulant therapy. We previously reported from a prospective randomized trial that early postoperative prophylaxis with a PPI is the most effective treatment, and could be considered mandatory, to prevent upper GI complications after open heart surgery [1] . Generally, however, most of the patients who are taking PPIs use one or more drugs with the potential for interaction with PPIs. McCarthy et al. have reported that adverse drug events are significantly increased for combination therapies with a PPI and warfarin, clarithromycin, corticosteroids, carbamazepins or nifedipine [3] . In particular, patients receiving a PPI concomitantly with warfarin have the highest rates of adverse drug events overall versus those receiving warfarin alone [3] . Despite adverse drug events, in a large number of patients undergoing cardiac surgery, warfarin is required to prevent prosthetic valve-related thrombosis or post-CABG graft occlusion. In our institution, lansoprazole or rabeprazole have been randomly prescribed for patients undergoing cardiac surgery since the evidence for the effect of PPIs was identified in a previous trial using rabeprazole [1] . In that trial, more than 80 % of the patients were taking warfarin, but there were no bleeding complications related to higher INR in the patients taking warfarin and rabeprazole. Recently, however, we noticed that some patients' INR increased dramatically to > 3.0. It is generally accepted that warfarin sodium can cause major or fatal bleeding. Coadministration of omeprazole with warfarin has been shown to cause marginal increases in prothrombin times [4, 5] , and the risk of significant bleeding during omeprazole and warfarin combination therapy is clearly increased [3] . Omeprazole is ranked eighth in the top 20 products spontaneously reported to the FDA under the Med Watch post-marketing surveillance system for monitoring suspected adverse drug reactions, and has been entered in the Adverse Event Rate System [6] . On the other hand, lansoprazole has not appeared on the list. Recently, however, the FDA has suggested that lansoprazole also increases INR when used concomitantly with warfarin [2] . In the present study, initial INR was significantly increased in patients taking lansoprazole compared with those taking rabeprazole. In our institution, post-cardiotomy patients were administered 3 mg warfarin from postoperative day 1 and the same dose was maintained until postoperative day 4. The dose of warfarin was adjusted after checking the initial INR, but the second INR still had a tendency to be high in patients taking lansoprazole, compared with the patients taking rabeprazole. Bleeding is more likely to occur during the initial period because of the higher INR [7] . In the present study, five patients experienced the complication of delayed cardiac tamponade from postoperative day 5 to 14. They were taking lansoprazole and warfarin concomitantly. In these patients, the postoperative pericardial drain was removed by postoperative day 3, after confirming that bleeding from the drain had stopped. However, INR may have gradually increased to > 3.0 and oozing of blood might have continued. All the patients were taken back to the intensive care unit. After pericardial redrainage, we replaced lansoprazole with rabeprazole, and the INR levels stabilized between 1.5 and 2.0. Furthermore, in the other two patients, INR increased suddenly after replacing the rabeprazole with lansoprazole and bleeding complications occurred. These events are obviously adverse drug events due to the concomitant use of warfarin and lansoprasole. PPIs alter the metabolism and pharmacokinetics of several commonly prescribed medications, either by interacting with components of the CYP enzyme system, or occasionally by altering drug absorption [8, 9] . The metabolism of PPIs and warfarin is mainly catalyzed by the CYP 450 isoenzyme, CYP2C19 [10] . Therefore, if PPIs are used concomitantly with warfarin, competitive inhibition can be predicted between the two drugs. In particular, omeprazole and lansoprazole are well metabolized by CYP2C19 [10] . On the other hand, rabeprazole is metabolized mainly via nonenzymatic reduction to a thioether compound, with only minor CYP2C19 involvement [10 -12] . Therefore, omeprazole and lansoprazole are potent competitive inhibitors of CYP2C19 substrates [13] . In the present study, it was considered that the metabolism of warfarin by CYP2C19 might be inhibited by lansoprazole, and the plasma concentration of warfarin become greater, causing delayed bleeding. In contrast, rabeprazole has less potential to inhibit the metabolism of CYP2C19 substrates, approximately half that of omeprazole [14] . In the present study, therefore, rabeprazole might not have affected the anticoagulative effect of warfarin. With warfarin therapy, it is necessary to keep checking the delicate balance between bleeding and thrombosis by confirming the blood clotting level. In particular, it is necessary to take care of bleeding or thrombosis when concomitant medications are used with warfarin. Therefore, it is important to select the concomitant drug which has the least effect on the anticoagulative effect of warfarin. In the present study, results suggest that rabeprazole is the more suitable PPI for controlling warfarin therapy.
Study Limitation
!
This study has several limitations. It is a retrospective analysis of a single institution. The sample size may thus be somewhat small. We have to keep observing the patients.
Conclusion
!
These results suggest that lansoprazole emphasizes the effects of warfarin, and so increases INR. On the other hand, rabeprazole has no influence on INR. Therefore, care needs to be taken when administering PPIs. In particular, the use of lansoprazole concomitantly with warfarin after open heart surgery should be avoided.
